In Vitro activities of clindamycin, imipenem, metronidazole, and piperacillin-tazobactam against susceptible and resistant isolates of Bacteroides fragilis evaluated by kill kinetics

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3413-3416

  Schaumann, Reiner ^a   Funke, Matthias ^a   Janssen, Eva ^a   Rodloff, Arne C ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; IMIPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; CONTROLLED STUDY; IN VITRO STUDY; KILL KINETICS; KINETICS; MICROBIOLOGICAL PARAMETERS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; BACTEROIDES FRAGILIS; CLINDAMYCIN; IMIPENEM; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PIPERACILLIN;

EID: 84861164809     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00099-12     Document Type: Article

References (29)

1. Betriu C, et al. 2008. Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. Antimicrob. Agents Chemother. 52:2686-2690. (Pubitemid 351915711)
2. Boselli E, et al. 2003. Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit. Care Med. 31:2102-2106. (Pubitemid 37011688)
3. Brazier JS, Stubbs SL, Duerden BI. 1999. Metronidazole resistance among clinical isolates belonging to the Bacteroides fragilis group: time to be concerned? J. Antimicrob. Chemother. 44:580-581. (Pubitemid 29490637)
4. Eklund AE, Nord CE, Swedish Study Group. 1993. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. J. Antimicrob. Chemother. 31(Suppl. A):79-85. (Pubitemid 23078099)
5. Erasmo AA, et al. 2004. Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patients with intra-abdominal infection. Asian J. Surg. 27:227-235. (Pubitemid 39094901)
6. European Committee on Antimicrobial Susceptibility Testing. 2012. EUCAST clinical breakpoint table v.2.0, valid from 2012-01-01. European Committee on Antimicrobial Susceptibility Testing, Basel, Switzerland. http://www.eucast.org.
7. Fille M, Mango M, Lechner M, Schaumann R. 2006. Bacteroides fragilis group: trends in resistance. Curr. Microbiol. 52:153-157. (Pubitemid 43260451)
8. Flaherty JF, et al. 1988. Comparative pharmacokinetics and serum inhibitory activity of clindamycin in different dosing regimens. Antimicrob. Agents Chemother. 32:1825-1829.
9. Golan Y, et al. 2003. Emergence of fluoroquinolone resistance among Bacteroides species. J. Antimicrob. Chemother. 52:208-213. (Pubitemid 36986881)
10. Hedberg M, Nord CE. 2003. ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clin. Infect. Dis. 9:475-488. (Pubitemid 36833791)
11. Houghton GW, Thorne PS, Smith J, Templeton R, Collier J. 1979. Comparison of the pharmacokinetics of metronidazole in healthy female volunteers following either a single oral or intravenous dose. Br. J. Clin. Pharmacol. 8:337-341. (Pubitemid 10229586)
12. Jhee SS, Kern JW, Burm JP, Yellin AE, Gill MA. 1995. Piperacillintazobactam pharmacokinetics in patients with intraabdominal infections. Pharmacotherapy 15:472-478.
13. Karjagin J, Pähkla R, Karki T, Starkopf J. 2005. Distribution of metronidazole in muscle tissue of patients with septic shock and its efficacy against Bacteroides fragilis in vitro. J. Antimicrob. Chemother. 55:341-346. (Pubitemid 40425459)
14. Kinzig M, Sörgel F, Brismar B, Nord CE. 1992. Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery. Antimicrob. Agents Chemother. 36:1997-2004.
15. Männistö P, et al. 1984. Concentrations of metronidazole and tinidazole in female reproductive organs after a single intravenous infusion and after repeated oral administration. Infection 12:197-201. (Pubitemid 14089022)
16. Mueller M, de la Peña A, Derendorf H. 2004. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob. Agents Chemother. 48:369-377. (Pubitemid 38141689)
17. Nagy E, Urbán E, Nord CE, ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. 2011. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience. Clin. Microbiol. Infect. 17:371-379.
18. Niinikoski J, et al. 1993. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections. Surg. Gynecol. Obstet. 176:255-261. (Pubitemid 23073572)
19. Occhipinti DJ, et al. 1997. Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens. Antimicrob. Agents Chemother. 41:2511-2517. (Pubitemid 27467565)
20. Olsen I, Solberg CO, Finegold SM. 1999. A primer on anaerobic bacteria and anaerobic infections for the uninitiated. Infection 27:159-165. (Pubitemid 29257738)
21. Oteo J, Aracil B, Alós JI, Gómez-Garcés JL. 2000. High prevalence of resistance to clindamycin in Bacteroides fragilis group isolates. J. Antimicrob. Chemother. 45:691-693. (Pubitemid 30255653)
22. Paradis D, et al. 1992. Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. Antimicrob. Agents Chemother. 36:2085-2092.
23. Schaumann R, Ackermann G, Pless B, Claros MC, Rodloff AC. 1999. In vitro activities of gatifloxacin, two other quinolones, and five nonquinolone antimicrobials against obligately anaerobic bacteria. Antimicrob. Agents Chemother. 43:2783-2786. (Pubitemid 29519565)
24. Schaumann R, et al. 2000. In vitro activities of fourteen antimicrobial agents against obligately anaerobic bacteria. Int. J. Antimicrob. Agents 16:225-232.
25. Schaumann R, Petzold S, Fille M, Rodloff AC. 2005. Inducible metronidazole resistance in nim-positive and nim-negative Bacteroides fragilis group strains after several passages metronidazole containing Columbia agar plates. Infection 33:368-372. (Pubitemid 41552015)
26. Snydman DR, et al. 2002. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends for 1997-2000. Clin. Infect. Dis. 35(Suppl. 1):S126-S134.
27. Stratton CW, Weeks LW, Aldridge KE. 1987. Comparison of kill-kinetic studies with agar and broth microdilution methods for determination of antimicrobial activity of selected agents against members of the Bacteroides fragilis group. J. Clin. Microbiol. 25:645-649. (Pubitemid 17041860)
28. Wexler HM. 2007. Bacteroides: the good, the bad, and the nitty-gritty. Clin. Microbiol. Rev. 20:593-621. (Pubitemid 47623770)
29. Zabinski RA, et al. 1993. Evaluation of activity of temafloxacin against Bacteroides fragilis by an in vitro pharmacodynamic system. Antimicrob. Agents Chemother. 37:2454-2458. (Pubitemid 23324473)